ArticlePloS one2025
Synthesis, characterization and drug loading properties of a medical metal-organic framework constructed from bioactive curcumin derivatives.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel medical metal-organic framework was successfully synthesized using curcumin derivatives, specifically 3, 5-bis (4-hydroxy-3-methoxystyryl) pyrazole, as ligands. These derivatives exhibit enhanced stability and potent anticancer and anti-inflammatory activities. The material named medi-MOF-2 was constructed using biocompatible zinc ions and characterized for its structural and functional properties. It exhibited permanent porosity with a Brunauer-Emmett-Teller (BET) surface area of 264 m2/g. Pore size distribution analysis revealed a micropore volume of 0.146 cm3/g and an average pore diameter of 11.92 Å. Medi-MOF-2 demonstrated a remarkable ibuprofen loading capacity of 160 mg/g, enabling the simultaneous release of both curcumin derivatives and ibuprofen. This dual-release mechanism highlights the potential of medi-MOF-2 in achieving synergistic drug effects upon further validation, thereby advancing the application of MOFs in the pharmaceutical field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.